2025 Q4 -tulosraportti
16 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 140 | - | - | ||
| 610 | - | - | ||
| 250 | - | - | ||
| 200 | - | - | ||
| 400 | - | - |
Ylin
22,5VWAP
Alin
20,8VaihtoMäärä
2,1 97 788
VWAP
Ylin
22,5Alin
20,8VaihtoMäärä
2,1 97 788
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenSomething is happening here... 125 mill turnover·1 päivä sittenAccording to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
·2 päivää sittenFor those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
·13.2.Even with similar (weak) growth as last year, this year's revenue will pass 600 mill. Hopefully well over. That is more than e.g. PHO, which has more than 3 times higher mCap than NAVA.·13.2.But 1600 shares traded during the day at low prices indicates that nobody cares about NAVA. Not exciting enough?·17.2.Have topped up at a level around the issue price recently, so the excitement lies in whether I can buy even cheaper? I think many are a bit too hasty with this stock, as it's not in this or next quarter that things will start to fall into place, but a bit further ahead. By then, the pricing will probably already have been adjusted up a few notches, I believe. If no other difficulties arise (which is always a risk), a time horizon of 2/3-5 years applies if it's to make money. I think.
·12.2.Always a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.
·12.2.I disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·12.2.Sure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
16 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenSomething is happening here... 125 mill turnover·1 päivä sittenAccording to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
- ·2 päivää sittenFor those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "
- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
- ·13.2.Even with similar (weak) growth as last year, this year's revenue will pass 600 mill. Hopefully well over. That is more than e.g. PHO, which has more than 3 times higher mCap than NAVA.·13.2.But 1600 shares traded during the day at low prices indicates that nobody cares about NAVA. Not exciting enough?·17.2.Have topped up at a level around the issue price recently, so the excitement lies in whether I can buy even cheaper? I think many are a bit too hasty with this stock, as it's not in this or next quarter that things will start to fall into place, but a bit further ahead. By then, the pricing will probably already have been adjusted up a few notches, I believe. If no other difficulties arise (which is always a risk), a time horizon of 2/3-5 years applies if it's to make money. I think.
- ·12.2.Always a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.·12.2.I disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·12.2.Sure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 140 | - | - | ||
| 610 | - | - | ||
| 250 | - | - | ||
| 200 | - | - | ||
| 400 | - | - |
Ylin
22,5VWAP
Alin
20,8VaihtoMäärä
2,1 97 788
VWAP
Ylin
22,5Alin
20,8VaihtoMäärä
2,1 97 788
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
16 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenSomething is happening here... 125 mill turnover·1 päivä sittenAccording to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
- ·2 päivää sittenFor those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "
- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
- ·13.2.Even with similar (weak) growth as last year, this year's revenue will pass 600 mill. Hopefully well over. That is more than e.g. PHO, which has more than 3 times higher mCap than NAVA.·13.2.But 1600 shares traded during the day at low prices indicates that nobody cares about NAVA. Not exciting enough?·17.2.Have topped up at a level around the issue price recently, so the excitement lies in whether I can buy even cheaper? I think many are a bit too hasty with this stock, as it's not in this or next quarter that things will start to fall into place, but a bit further ahead. By then, the pricing will probably already have been adjusted up a few notches, I believe. If no other difficulties arise (which is always a risk), a time horizon of 2/3-5 years applies if it's to make money. I think.
- ·12.2.Always a positive headline on the quarterly reports, higher sales, higher ebitda etc. But if you know the company, you know what's coming. There's always something further down in the financial statements that ruins it and the money drains away. So this time too, they manage to lose over 11 million kroner on the bottom line. They never manage to be left with money; costs just increase proportionally.·12.2.I disagree here. Positive cash flow in the quarter of 14m from operations which is quite on par with EBITDA, meaning that most comes from actual sales and not adjustment of working capital items. The loss on the bottom line comes from a larger write-down in the quarter, where parts come from Dne Pharma which is now consolidated into the figures, as well as I suspect that a further write-down of loans to Observe is included here. Lars Hjarrand has probably done a lot of good over the years, but in the last 2årene I think choices were made that made it seem like he wasn't as "on it". Very pleased that the new CFO shows new initiatives and takes action and shares a concrete plan to reduce the debt that has accumulated. That it will be a cleanup job and that there is enough to tackle, I would assume, but I think they show new momentum and I am positive.·12.2.Sure, they had decent cashflow. But I think the report was weak, they are reducing earnings in the important consumer health area, sales of Mysimba (weight loss drug) are falling 20%(!) and they are losing over 11 mill kr before tax. This is how I feel almost every single report is, I've owned them for some years now. It has been a terrible investment.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 140 | - | - | ||
| 610 | - | - | ||
| 250 | - | - | ||
| 200 | - | - | ||
| 400 | - | - |
Ylin
22,5VWAP
Alin
20,8VaihtoMäärä
2,1 97 788
VWAP
Ylin
22,5Alin
20,8VaihtoMäärä
2,1 97 788
Välittäjätilasto
Dataa ei löytynyt